Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Gian Life CareBOM:542918 -0.41%59 EBITDA Margin % is 29.80% as of Dec. 2025, which is at its 10-year median of 29.80. GuruFocus rates BOM:542918 with a GF Score™ of 59/100 and a GF Value™ of ₹5.88 (Modestly Undervalued). The stock has 4 warning signs investors should review. Among 203 Medical Diagnostics & Research companies, Gian Life Care ranks worse than 55.17% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. Gian Life Care's EBITDA for the
three
months ended in Dec. 2025 was ₹3.35 Mil. Gian Life Care's Revenue for the
three
months ended in Dec. 2025 was ₹11.23 Mil. Therefore, Gian Life Care's EBITDA margin for the quarter that ended in Dec. 2025 was 29.80%.
Gian Life Care (BOM:542918) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Gian Life Care EBITDA Margin % Related Terms
Gian Life Care EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Gian Life Care's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BOM:542918 vs TMO, DHR, IDXX: EBITDA Margin % Comparison
For the Diagnostics & Research subindustry, Gian Life Care's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Gian Life Care EBITDA Margin % vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Gian Life Care's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Gian Life Care's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Gian Life Care (BOM:542918) has a EBITDA Margin % of 29.80% as of Dec. 2025. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Gian Life Care and its competitors. This is near median its historical median of 29.80. Over the past decade, Gian Life Care's EBITDA Margin % has ranged from 1.53 to 51.39. According to the industry distribution chart, Gian Life Care ranks #112 out of 203 companies in the Medical Diagnostics & Research industry, placing it in the top 55.2%.
Is Gian Life Care's EBITDA Margin % too high?
Gian Life Care's current EBITDA Margin % of 29.80% is near median its 10-year median of 29.80. Over the past 10 years, this metric has ranged from a low of 1.53 to a high of 51.39. The Medical Diagnostics & Research industry median EBITDA Margin % is 5.43. Gian Life Care's value of 29.80% is 448.8% above this industry median. Based on the distribution chart, Gian Life Care ranks #112 out of 203 companies in the Medical Diagnostics & Research industry, which is below the industry midpoint. Overall, Gian Life Care has a GF Score™ of 59/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Gian Life Care's EBITDA Margin % compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Gian Life Care ranks #112 out of 203 companies for EBITDA Margin %. This places Gian Life Care in the lower half of its industry. The industry median EBITDA Margin % is 5.43. Gian Life Care's value of 29.80% is 448.8% above this benchmark. Historically, Gian Life Care's own EBITDA Margin % has ranged from 1.53 to 51.39 over the past decade. While the company's 10-year median is 29.80 vs. the industry median of 5.43, Gian Life Care has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Medical Diagnostics & Research company?
The median EBITDA Margin % among Medical Diagnostics & Research companies is 5.43, based on 203 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Gian Life Care's current EBITDA Margin % of 29.80% is 448.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Gian Life Care and its competitors. For the Medical Diagnostics & Research industry, the median EBITDA Margin % is 5.43 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Gian Life Care's current EBITDA Margin % is 29.80%, which is near median its own 10-year median of 29.80. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Gian Life Care stock overvalued right now?
Based on GuruFocus' analysis, Gian Life Care (BOM:542918) is currently considered Modestly Undervalued. The stock's GF Value™ is ₹5.88, compared to a current price of ₹4.91 — trading 16.5% below its estimated fair value. The current EBITDA Margin % is 29.80%, which is near median its 10-year median of 29.80 and 448.8% above the Medical Diagnostics & Research industry median of 5.43. Gian Life Care's overall GF Score™ is 59/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Gian Life Care (BOM:542918), the current EBITDA Margin % is 29.80% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Gian Life Care (BOM:542918) Overvalued in 2026?
Based on GuruFocus' analysis, Gian Life Care stock appears to be undervalued.
The current stock price of ₹4.91 is trading 16.5% below its estimated GF Value™ of ₹5.88.
GuruFocus considers Gian Life Care to be Modestly Undervalued.
Key valuation signals for BOM:542918:
EBITDA Margin %: 29.80% (near median its 10-year median of 29.80)
GF Value™: ₹5.88 vs. price of ₹4.91 (16.5% below fair value)
Industry Position: 448.8% above the Medical Diagnostics & Research median (#112 of 203)
No single metric tells the full story. See the BOM:542918 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Gian Life Care Ltd is an Indian firm engaged in the business of providing diagnostic and related healthcare tests and services in Kanpur and nearby areas. The company provides a broad range of diagnostic and related healthcare tests and services such as patient diagnosis, prevention, and wellness diagnosis services to its patients and healthcare providers. Its customers include individual patients, hospitals, other healthcare providers, and corporate customers. Substantial revenue accrues from the Pathological Testing Fees. The company has only one operating segment namely, Laboratories Pathological Investigations.
59GF Score
Get the complete analysis for BOM:542918
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:542918 has been successfully added to your 
